Cspc Baike (shandong) Biopharmaceutical Co., Ltd.

This study tested a new medicine called TG103, given as a weekly shot, in 465 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. The goal was to see if TG103 could lower blood sugar levels and help with weight loss. The study is now …

This study tested a new weekly injection (HD1916) similar to semaglutide for helping obese adults lose weight. 462 non-diabetic participants received the drug for 44 weeks. The main goal was to see how much weight they lost compared to a standard treatment.

This study tested a new injectable drug called TG103, taken with the common diabetes pill metformin, in 632 adults with type 2 diabetes. The goal was to see if TG103 helps lower blood sugar better than an existing drug (dulaglutide) over 28 weeks. Participants had poorly controll…